|
February 05, 2007 NASD OTC-BB: MRDAF
Health Canada Approves Meridian¡¯s Digital Pulse Analyzer
Meridian Co., Ltd. ("Meridian" or the "Company") (OTC BB:MRDAF.OB - News) is pleased to announce that it has received approval from Health Canada for the sale of the Company¡¯s proprietary Digital Pulse Analyzer (DPA) to the health industry throughout Canada.
The device was launched in the United States in 2003, after successfully being marketed and sold throughout South Korea and China in 2002.
The company has been eagerly awaiting the opportunity to launch the Digital Pulse Analyzer in Canada as Meridian¡¯s North American Corporate and Distribution office, Belgium Medical Inc. (¡°MMI¡±), is located in Vancouver, British Columbia, Canada. MMI has been the principal architect of the success of the DPA device and screening methodologies that are being marketed through distribution channels in the United States and can now extend that effort to supporting distribution channels in the Canadian market.
Recently, Meridian¡¯s DPA product has come to the attention of providers of health care services to the US federal government because of the product¡¯s safe and simple means of assisting in cardiovascular health screening programs. The Company¡¯s management believes that this recent attention and the Canadian regulatory approval are both significant milestones that create more wide-spread awareness about Meridian and its products.
More About: Digital Pulse Analyzer ("DPA")
The DPA accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA-cleared device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.
The Company feels that use of the DPA can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the number one killer of both men and women in the United States with an estimated economic cost of approximately $298 billion.
More About: Meridian Co. Ltd.
Meridian is an established leader in the research/development, manufacturing and sales of integrative medical equipment. The Company sells its products and equipment to a wide range of customers in the global health care industry. The Company presently holds a total of 18 worldwide patents on its technology, and has received FDA approval, as well as other international regulatory approvals, for many of its products.
On Behalf of the Board of Directors, Hyeon Seong Myeong President
This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.
Contact:
Meridian Co., Ltd.
Peter Holeczek
Corporate Communications
1-866-736-3306
Website: https://MeridianMedical.ca
|